Wednesday, July 6, 2016

BRIEF-FDA grants Merrimack fast track designation for Seribantumab (mm-121) in non-small cell lung cancer

* FDA Grants Merrimack fast track designation for

Seribantumab (Mm-121) in non-small cell lung cancer

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)